Evidence map›Paper›PMID 37718481›Full record

ArticleBiotechnology journal2024

Investigating dynamics of lentiviral vector secretion from HEK293T producer cells using a fractionated perfusion system.

Lauren M Timmins, Patrick Erickson, Biju Parekkadan

Open access · hybridAbstract read
In one paragraph

Article in Biotechnology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Lauren M TimminsDepartment of Biomedical Engineering, Rutgers University, Piscataway, New Jersey, USA.
Patrick EricksonDepartment of Chemical and Biochemical Engineering, Rutgers University, Piscataway, New Jersey, USA.
Biju ParekkadanDepartment of Biomedical Engineering, Rutgers University, Piscataway, New Jersey, USA.ORCID https://orcid.org/0000-0002-3408-8085
Rutgers, The State University of New Jersey · US

Funding

Artificial, Humanized Stem Cell NichesR01EB012521 · NIBIB · RUTGERS, THE STATE UNIV OF N.J. · PI PAREKKADAN, BIJU · 2011 to 2021
$6.0M
Genetic-engineered control of the immunogeneic state of vascular composite allografts during preservationR01EB028782 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI Biju Parekkadan, Korkut Uygun · 2021 to 2026
$3.1M
NIBIB NIH HHS R01 EB012521NIBIB NIH HHS R01 EB028782
6 · The paper itself

Abstract

Mammalian cell culture is quickly becoming the go to engineering vehicle to mass produce viral vectors in a manner that is safe, convenient, reproducible, and cost and scale effective. Human embryonic kidney (HEK293) cells, in particular, have been utilized and customized (via differentiated transgene expression, modified culture parameters, addition of cytostatic culture agents) to increase vector yields. However, less attention has been made to understanding innate processes within the cells (such as, immune response, cell cycle, metabolism) themselves to better control or increase viral vector product yield. Accordingly, herein, the variation in viral production was studied from HEK cells over time using a one-way perfusion system and bioreactor to study the impact of external factors on secretion dynamics without retrotransduction. Specifically, the impact of cell density on viral titer, transduction efficiency, and LDH, was studied. Next, we look at the impact of using an inflammatory reporter cell line on viral output, and the secretion dynamics from HEK cells when we use sodium butyrate (cell cycle arrest agent). Lastly, we assess how downregulation of the PDK pathway increases viral titer. Altogether, we investigated the impact of various interventions to increase transient protein expression and viral output from HEK cells in a controlled and measurable environment to ultimately increase the efficiency of HEK cells for downstream clinical applications.

Indexed as

Genetic VectorsLentivirusAnimalsCell Culture TechniquesHEK293 CellsHumansMammalsPerfusiongene therapyHEK-viral interactionsstable viral productionvector manufacturing

Identifiers

PMID37718481
PMCPMC11289840
OpenAlexW4386818333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.